Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Akebia reported Q2 total revenue of $49.1 million, down from $62.5 million year-over-year, as growth in Vafseo sales to $21.3 million was offset by a decline in Auryxia revenue due to generic competition. Operational highlights include positive interim data from the VOICE trial showing improved safety outcomes for Vafseo versus ESAs, and the initiation of a Phase 2 trial for ebribafusp in rare kidney diseases.
Key figures
- Revenue
- 49100000
- Net loss
- 8900000
- Cash position
- 155500000
- Vafseo revenue
- 21300000
- Auryxia revenue
- 25500000
- Vafseo patients
- 10500
- Restructuring expense
- 1900000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.